This study tests a medicine called icovamenib for adults with Type 2 Diabetes (T2D) who are using Ozempic but still have high blood sugar. The trial lasts for 52 weeks, just over a year. Participants will either receive icovamenib or a placebo (a harmless pill that doesn't affect your body) alongside their Ozempic treatment.

The main aim is to see if icovamenib helps lower blood sugar levels more effectively than just Ozempic alone. The study is double-blind, meaning neither the doctors nor the participants know who is receiving the actual medicine, which helps ensure unbiased results.

To join, you must be aged between 18 and 70, have been taking Ozempic and had stable doses for at least 3 months, and meet certain health criteria. You cannot join if you have Type 1 Diabetes or certain other health issues.

• Length: 52 weeks
• Visits: Multiple check-ups required
• Eligibility: Specific health criteria and current Ozempic use